A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Disease

• Status: Not yet recruiting
• Trial end date: 2027-06-01

Summary

It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension associate with left heart disease (PH-LHD) by right heart catheterization.

• Phase: Phase 3

Details

• Lead Sponsor: Pulnovo Medical (Wuxi) Co., Ltd.
• Collaborators: Beijing Anzhen Hospital; Cangzhou Central Hospital; China-Japan Union Hospital, Jilin University; First Affiliated Hospital of Fujian Medical University; First Affiliated Hospital of Harbin Medical University; First Affiliated Hospital of Wenzhou Medical University; First Affiliated Hospital Xi'an Jiaotong University; First Hospital of Tsinghua University; Fuwai Yunnan Cardiovascular Hospital; Guangdong Provincial People's Hospital; RenJi Hospital; Renmin Hospital of Wuhan University; Second Hospital of Jilin University; Shanghai 10th People's Hospital; Shanxi Cardiovascular Hospital; Shengjing Hospital; Sichuan Academy of Medical Sciences; TEDA International Cardiovascular Hospital; The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Soochow University; The First Affiliated Hospital with Nanjing Medical University; The General Hospital of Northern Theater Command; Tianjin Medical University General Hospital; Tongji Hospital; West China Hospital; Wuhan University; Xiamen Cardiovascular Hospital, Xiamen University; Zhejiang University